In silico trials company raises five million euros

9 January 2020

Novadiscovery, a French pioneer in the use of in silico clinical trials to predict drug efficacy and optimize clinical development, has raised five million euros ($6 million) in a Series A financing.

The investment arm of Debiopharm, a private, Swiss corporate fund specializing in smart data and digital health, has led the round, which will allow Novadiscovery to scale its in silico clinical trial simulation platform, which is called Jinkō.

François-Henri Boissel, chief executive and co-founder of Novadiscovery, said: “We have seen the significant positive impact our in silico trials platform can have on reducing R&D costs and compressing time-to-market for new drugs and in drug repositioning.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK